UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO).
“The opening of this trial in MDS and MF marks another critical step forward on the development path for SP-420,” said AbFero’s CEO Thomas X. Neenan. “Following the recently awarded Parkinson’s research grants from EUREKA Eurostars and Cure Parkinson’s, this trial is an additional building block in our strategy of developing safe chelators for both hematological indications and diseases of aging where iron is implicated.”Learn more about Abfero Pharmaceuticals Announces Initiation of Phase 1 Study for Lead Iron Chelator.
Related news:AbFero to Receive € 2M Eurostars Funding for Parkinson’s Disease Therapy. AbFero Pharmaceuticals Announces Funding From Cure Parkinson’s for Lead Compound SP-420.